ADVA launches auto-tunable transceiver to help operators easily scale access networks to 25G
15.9.2022 10:00:00 EEST | Business Wire | Press release
ADVA (FSE: ADV) today launched its AccessWave25™, empowering network operators to easily migrate their 10Gbit/s access infrastructure to 25Gbit/s connectivity without a significant increase in footprint or major changes to the existing optical layer. The pluggable device answers the urgent need for higher bandwidth services in mobile X-Haul, cable access and wholesale networks. Operators can now slot the AccessWave25™ into any standard-based SFP28 port for an instant capacity upgrade without replacing existing demarcation or aggregation devices. Using patent-pending distance optimization technology, the device also extends 25Gbit/s DWDM reach to 40km, and its G.metro auto-tuning technology reduces provisioning efforts and simplifies operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220914005787/en/
ADVA’s AccessWave25™ offers an easy route to 25G DWDM connectivity in access networks without any major upgrades. (Photo: Business Wire)
“Our AccessWave25™ is the key to unlocking more bandwidth at the edge. Now network operators have an easy, low-cost way to address soaring bandwidth consumption that doesn’t require extra real estate or cause major disruption to services. And as well as boosting capacity, the AccessWave25™ offers a substantial increase in reach. While today’s solutions can’t go beyond 15km, our new pluggable device uses PAM4 modulation and direct-detection technology to support data transport up to 40km,” said Christoph Glingener, CEO of ADVA. “Simple to deploy and ideally suited for outdoor use, our AccessWave25™ device will be the foundation for the next generation of optical access networks.”
ADVA’s AccessWave25™ plug enables the seamless upgrade of fiber-based access networks. Host-agnostic and with a standardized SFP28 form factor, it empowers operators to instantly connect switches, routers and many other devices to DWDM open line systems. With full C-band tunable interfaces and G.metro self-tuning capabilities, the device reduces set-up time, minimizes human error and delivers operational cost savings. Network operators can also use the G.metro communication channel to remotely monitor the status and health of plugs for easy troubleshooting of any issues. Using less than 3 watts and with an I-temp hardened design, the AccessWave25™ is perfect for deployment in a wide range of outdoor settings.
“The latest addition to our pluggable technology portfolio answers the most urgent needs of our customers in a wide range of industries. From the core to the metro to access networks, our product range offers a plug for almost every situation,” commented Saeid Aramideh, VP of business development at Optical Engines, ADVA. “OurAccessWave25™ is a vital addition to our AccessWave™ family of pluggable devices and features our latest G.metro technology. Either with a third-party OLS or with our turnkey FSP 3000 solution for passive optical access networks, our pluggable technology provides the tools for tackling relentless growth in data consumption as well as the ever-changing demands of optical access networks.”
Further details on the ADVA AccessWave25™ are available in these slides: https://adva.li/accesswave25-slides.
A supporting product video is also available here: https://youtu.be/bcV06nMJ3_c.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220914005787/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom